Poly(ADP-ribose) polymerase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Poly(ADP-ribose) polymerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly(ADP-ribose) polymerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Poly(ADP-ribose) polymerase inhibitors: Overview
Poly (ADP-ribose) polymerase inhibitors, which are often called PARP inhibitors, are targeted therapies that are used to treat cancer. PARP is a protein that has a role in cellular growth, regulation and cell repair which helps the cancer cells repair themselves and survive. The PARP inhibitor stops the cancer cells being repaired which causes the cells to die and so reduces tumor growth. In cancers where the tumor suppressor gene is faulty the cancer cells are repaired only by PARP. The PARP repair is incomplete which means the cancer cells DNA is repaired to a point where it just has a small amount of damage and the cancer cells are able to able to grow and divide. If the PARP did not repair the DNA then the cancer cells would have too much damage in its DNA so would trigger its own death. The PARP inhibitors act to stop the cancer cells DNA being repaired by PARP, so the damaged DNA stays at the critical level that causes cell to trigger its own death and therefore inhibits the growth of the tumor.
Report Highlights
This segment of the Poly(ADP-ribose) polymerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Poly(ADP-ribose) polymerase inhibitors Emerging Drugs
Further product details are provided in the report……..
Poly(ADP-ribose) polymerase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Poly(ADP-ribose) polymerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Poly(ADP-ribose) polymerase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Poly(ADP-ribose) polymerase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Poly(ADP-ribose) polymerase inhibitors drugs.
Poly(ADP-ribose) polymerase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Poly(ADP-ribose) polymerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly(ADP-ribose) polymerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Poly(ADP-ribose) polymerase inhibitors: Overview
Poly (ADP-ribose) polymerase inhibitors, which are often called PARP inhibitors, are targeted therapies that are used to treat cancer. PARP is a protein that has a role in cellular growth, regulation and cell repair which helps the cancer cells repair themselves and survive. The PARP inhibitor stops the cancer cells being repaired which causes the cells to die and so reduces tumor growth. In cancers where the tumor suppressor gene is faulty the cancer cells are repaired only by PARP. The PARP repair is incomplete which means the cancer cells DNA is repaired to a point where it just has a small amount of damage and the cancer cells are able to able to grow and divide. If the PARP did not repair the DNA then the cancer cells would have too much damage in its DNA so would trigger its own death. The PARP inhibitors act to stop the cancer cells DNA being repaired by PARP, so the damaged DNA stays at the critical level that causes cell to trigger its own death and therefore inhibits the growth of the tumor.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Poly(ADP-ribose) polymerase inhibitors R&D. The therapies under development are focused on novel approaches for Poly(ADP-ribose) polymerase inhibitors.
This segment of the Poly(ADP-ribose) polymerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Poly(ADP-ribose) polymerase inhibitors Emerging Drugs
- Talazoparib: Pfizer
- Niraparib: Janssen
Further product details are provided in the report……..
Poly(ADP-ribose) polymerase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Poly(ADP-ribose) polymerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Poly(ADP-ribose) polymerase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Poly(ADP-ribose) polymerase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Poly(ADP-ribose) polymerase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Poly(ADP-ribose) polymerase inhibitors drugs.
Poly(ADP-ribose) polymerase inhibitors Report Insights
- Poly(ADP-ribose) polymerase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Poly(ADP-ribose) polymerase inhibitors drugs?
- How many Poly(ADP-ribose) polymerase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Poly(ADP-ribose) polymerase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Poly(ADP-ribose) polymerase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Poly(ADP-ribose) polymerase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pfizer
- Janssen
- Jiangsu HengRui Medicine
- Jeil Pharmaceutical
- Rhizen Pharmaceuticals
- Rakovina Therapeutics
- Ribon Therapeutics
- Cybrexa Therapeutics
- Waverley Pharma
- Idience
- IMPACT Therapeutics
- Cephalon
- Shanghai De Novo Pharmatech
- Clovis Oncology
- BeiGene
- Abbvie
- AstraZeneca
- NanoGhost
- Allarity Therapeutics
- Talazoparib
- Niraparib
- Fluzoparib
- Olaparib
- Veliparib
- Amelparib
- RP 12146
- CK 102
- 2X-121
- Pamiparib
- NG 1002
- SC 10914
- Rucaparib
- Research programme: kt 2000 PARP inhibitors
- Research programme: monoPARP inhibitors
- CBX 11
- Senaparib
- Venadaparib
Introduction
Executive Summary
Poly(ADP-ribose) polymerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Poly(ADP-ribose) polymerase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Talazoparib: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SC 10914: Shanghai De Novo Pharmatech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
CK 102: Cephalon
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CBX 11: Cybrexa Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Poly(ADP-ribose) polymerase inhibitors Key Companies
Poly(ADP-ribose) polymerase inhibitors Key Products
Poly(ADP-ribose) polymerase inhibitors- Unmet Needs
Poly(ADP-ribose) polymerase inhibitors- Market Drivers and Barriers
Poly(ADP-ribose) polymerase inhibitors- Future Perspectives and Conclusion
Poly(ADP-ribose) polymerase inhibitors Analyst Views
Poly(ADP-ribose) polymerase inhibitors Key Companies
Appendix
Executive Summary
Poly(ADP-ribose) polymerase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Poly(ADP-ribose) polymerase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Talazoparib: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
SC 10914: Shanghai De Novo Pharmatech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
CK 102: Cephalon
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CBX 11: Cybrexa Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Poly(ADP-ribose) polymerase inhibitors Key Companies
Poly(ADP-ribose) polymerase inhibitors Key Products
Poly(ADP-ribose) polymerase inhibitors- Unmet Needs
Poly(ADP-ribose) polymerase inhibitors- Market Drivers and Barriers
Poly(ADP-ribose) polymerase inhibitors- Future Perspectives and Conclusion
Poly(ADP-ribose) polymerase inhibitors Analyst Views
Poly(ADP-ribose) polymerase inhibitors Key Companies
Appendix